Median progression-free survival was significantly higher for the doxorubicin and ifosfamide group ( @ months -LSB- @ % CI @-@ -RSB- ) than for the doxorubicin group ( @ months -LSB- @-@ -RSB- ; HR @ -LSB- @ % CI @-@ -RSB- , stratified log-rank test p = @ ) .